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| CANCER CELL DISSEMINATION IS AN EARLY EVENT
Cancer cell dissemination has long been considered to be a late event in tumour development. However, accumulating evidence indicates that cancer cells spread much earlier than was previously believed, 8 even before the primary tumour is detected. 9 Tumour cells are frequently detected in the blood and bone marrow of cancer patients who have no clinical or even histopathologic signs of metastasis. 10 The variability in detection rates is likely due to differences in selection criteria and methodologies (Table 1) . Recent technological advances have greatly improved CTC detection meth-
ods. An advanced unique microfluidic platform (CTC-Chip) was found to identify CTCs in the peripheral blood of more than 90%
of patients with metastatic lung, prostate, pancreatic, breast cancer and colon cancer and did not detect CTCs in the healthy control.
In addition, CTCs were isolated in 100% of patients with earlystage prostate cancer using the same platform, 11, 12 indicating that the dissemination of cancer cells into the circulation may occur randomly. CTCs that home to the bone marrow are also detected in patients with pre-invasive lesions, suggesting that bloodborne dissemination is also an early event. 12 Given the much lower incidences of metastasis, the correlation between CTCs, DTCs and metastasis remains elusive. To date, the detection of CTCs and
DTCs remains a challenging diagnostic approach and prognostic biomarker, not only as a result of methodological limitations but also because the heterogeneity among CTCs and DTCs in bone marrow compromises their ability to predict the metastatic behaviours.
Neither CTC status nor DTC status has been included in routine clinical analysis. 13 
| BONE MARROW IS A RESERVOIR OF DISSEMINATED TUMOUR CELLS
Bone marrow is a critical site of immune cell development and erythropoiesis. The bone marrow parenchyma includes hematopoietic stem cells and hematopoietic progenitor cells. The stroma, which is composed of stromal stem cells, extracellular matrix and several types of secreted cytokines, is highly vascular and enriched with numerous blood vessels and capillaries. 14 Bone marrow is also a niche for mature plasma cells and memory T cells. 15 16 Bone marrow also represents a sanctuary site for DTCs derived from various additional types of epithelial tumours. 16 The presence of DTCs in the bone marrow is associated with not only bone metastasis but also the development of distant tumours. DTCs in the bone marrow may re-enter the vasculature and disseminate secondarily throughout the body. 17, 18 Although the dissemination of cancer cells into the circulation and the bone marrow is an efficient process, cancer metastasis is an 
| BON E MARROW FOR MS A PREMETASTATIC NICHE FOR DISSEMINATED TUMOUR CELLS
Secondary cancer growths do not occur randomly. 23 Stephen Paget's "seed and soil" hypothesis proposed that the homing and settlement of cancer cells depend on the fertile "soil" provided by a given microenvironment. Bone marrow is a major target organ for metastasis, providing a fertile "soil" for circulating tumour cells to settle and repopulate. 24 The fertile "soil" is sometimes formed before the arrival of circulating tumour cells, in which case it is termed a "premeta- used to detect gene translocation. 47 Multiregion genetic analysis of renal carcinomas revealed intratumour heterogeneity. 48 The phylogenetic reconstruction of those renal carcinomas also revealed branched evolutionary tumour growth, with 63%-69% of unique somatic mutations present in various tumour regions. 48 Nonmutagenic treatments, such as everolimus, did not cause more mutations compared to pretreatment; on the contrary, certain mutations in the primary cancer disappeared after treatment with everolimus, indicating that the treatment resulted in clonal selection. Prostate cancer, which is histologically multifocal, is an example. The primary tumour foci from similar physical regions were found to be more closely related, suggesting that cancer arises from an ancestor and undergoes divergent evolution thereafter. 49 The heterogeneity of CTCs reflects the heterogeneity of the primary cancer. Single-cell deep sequencing studies have shown that mutations or somatic single nucleotide variants (sSNVs) in CTCs could be found in subclones of the primary tumour and metastases, indicating the cell origin of the CTCs. 49 The identical genomic profiles for CTCs and the primary tumour reflect the linear model by which tumour cells are disseminated into the circulation. However, the colonization of CTCs in distant sites reflects the branching evolution model. CTCs overlap with more than 90% of primary cancer mutations but only 73% of metastatic mutations. 49 When the DNA copy aberration of the cells (CNA) was compared, the DTCs in bone marrow showed 53% CNA similarity with that of the primary tumour, whereas the majority of the DTCs in the bone marrow displayed genomic profiles unrelated to the primary tumour, indicating that the parallel evolution model applies to the disseminated cells in the bone marrow ( Figure 1 ).
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| Bone marrow is a dormant niche for DTCs
Metastasis is an inefficient process. Although the dissemination of cancer cells occurs at an early stage of cancer, many cancer cells delivered into the circulation either die or go into a dormant state. 52 The following three types of gene expression signatures have been identified in CTCs: low-proliferative signatures, biphenotypic signatures, in which both epithelial and mesenchymal markers are expressed, and epithelial-stromal interface signatures, in which igfbp5 is expressed. 53 Due to the short half-life of CTCs in circulation, which persist for only 1-2 hours, and due to apoptotic CTCs, the detection and prognostic value of CTCs in circulation has been unclear. Most CTCs die in circulation as a result of shear stress and/or anoikis. 54, 55 Contact with integrins and exposure to bonederived cytokines in the bone marrow can reduce proapoptotic signalling. 56, 57 The persistence of DTCs in the bone marrow during follow-up is an indicator of the prognosis. 58 Up to 40% of patients diagnosed with nonmetastatic breast cancer still have a significant risk of relapse, even after the complete surgical removal of the tumour, most likely because of the existence of DTCs. 51, 59 DTCs in the bone marrow are usually considered to be nonproliferative and are believed to be the source of metastasis, independent of the primary tumour site and the pattern of overt metastases. 10 More than 80% of patients with solid tumours harbour Ki67-negative DTCs in the bone marrow. 60 DTCs in the bone marrow exhibit very low or even no detectable pAKT levels. 61 Cancer cells invade the bone marrow, where they remain dormant and are protected from chemotherapy or hormonal therapies that could otherwise eradicate them.
The quiescence of DTCs depends on the cross-talk between the cancer cells and the bone marrow microenvironment. Bone marrow seems to be a particularly dormancy-inducing environment for DTCs.
Stable microvasculature constitutes a dormant niche for DTCs. osteoclasts. 65 TGF-β derived from osteoclasts was also shown to play roles in maintaining the quiescent state of cancer cells in the bone marrow. 65 The HSC niche may act as a permissive site for DTCs to escape from source of stress. DTCs may reside in close proximity to osteoblasts while expressing high levels of Axl, one of the tyrosine kinase receptors for growth arrest-specific 6 (GAS6). 81 In the interplay between DTCs and NK cells, the secretion of LDH5 and the ADAM10-mediated shedding of the NKG2D ligand MICA/MICB from CTCs prevents the recognition and elimination of the cells via NK cell-mediated lysis.
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On the other hand, cancer cells are regulated in the bone marrow by the immune system. The proportion of memory T cells among the CD4 and CD8 T cells was found to be much higher in the bone marrow of cancer patients compared with healthy donors (P < 0.001), suggesting that the immune equilibrium between DTCs and memory T cells is involved in the balance between dormant cancer cells and tumour escape. 84 Only some of these immunological changes were also detectable in peripheral blood samples. 84 have been shown to exhibit an enhanced invasive ability. 103 The dormant DTCs may be reactivated by the osteoclast-mediated release of bone-derived growth factors. 57 The interaction between the bone marrow niche and the cancer cells was involved cancerderived E-cadherin and osteogenic N-cadherin. 104 
| Human epidermal growth factor receptor 2 (HER2) and the estrogen receptor (ER)
Primary tumours and DTCs display a discordant ERα and HER2
status. 105 This discordance may be important for determining which patients will benefit from endocrine and/or HER2 targeted therapy. patients. 110 Clinically, liquid bioscopy helps to find DTCs in the bone marrow of patients with various types of solid tumours. 16 CTCs and DTCs have been reported as independent prognostic markers that impact the progression-free survival (PFS) and overall survival (OS). 13 The number of CTCs is also correlated with serum levels of other markers, such as the prostate cancer biomarker, PSA. 49 However, the inconsistency of these markers and the short half-life of CTCs limit their application as diagnostic and prognostic biomarkers in the clinical setting. It has been considered that CTCs are singly suspended in the circulation, but the amount of CTC clusters can be underestimated due to the lack of appropriate detection methods. 111 The survival rates of CTCs are highly variable, and EpCAM-negative and CD44-positive subsets exhibit quiescence properties and can initiate relapse or metastasis. CTCs were detected in 10% of the patients, and DTCs were detected in 14% of the same patients. 115 As DTCs in the bone marrow display a more malignant transformed phenotype, and the colonization of CTCs in the bone marrow is more like a selective process, DTCs in bone marrow are expected to be a superior marker for predicting overall survival, compared to CTCs. However,this conclusion is controversial. [114] [115] [116] [117] Some studies have demonstrated a superior performance of DTCs in predicting overall survival in patients with cancer. 118 In contrast, other studies reported that DTCs were associated with bone metastasis (P = 0.0001) but not with a poorer overall survival. 116 At this time,
DTCs have not been recommended as a substitute for CTCs as the prognostic biomarker, because bone marrow aspiration is invasive and uncomfortable for patients. However, the presence of bone marrow DTCs in patients with primary breast cancer is associated with a shorter relapse-free survival and locoregional relapse, although it is not an independent prognostic factor. 58, 119 The persistence of DTCs during follow-up has been shown to significantly predict the increased risk for subsequent relapse and death. 120 The importance of histologic or genetic subclassification of cancer lies principally in the tumour biology, especially the response to therapy and the outcome. DTC status has been included in the new American Joint Committee on cancer classification. 13 The presence of DTCs identified (at median 85 months follow-up) a subgroup of luminal A patients characterized by high expression levels of ER-related genes and low expression of the HER2 cluster and proliferation-associated genes. This subgroup was found to have particularly poor outcomes (P = 0.008); however, this finding was not apparent for other tumour subtypes. 121 DTCs, but not CTCs, are associated with DFS in node-negative patients. 115 Currently, no diagnostic tools are available to monitor the response after the completion of adjuvant treatment to identify patients who need secondary adjuvant therapy due to persistent tumour cell load.
The persistence of DTCs in the bone marrow after a disease-free follow-up interval indicates that DTCs in the bone marrow may be used as a surrogate marker to predict the risk of relapse, especially to identify patients with a poor response to therapy. The reevaluation of bone marrow status may be a promising tool because the presence of DTCs is a possible surrogate marker for persistent MRD.
Studies have shown that the persistence of DTCs in the bone marrow of patients with primary breast cancer after conventional adjuvant therapy is associated with a poor prognosis. 106 The existence of dormant DTCs in the bone marrow increases the risk of late relapse. When patients were followed for years, DTCs in the bone marrow were found to be a superior marker for predicting relapse.
The persistence of DTCs in the bone marrow during follow-up significantly predicted the increased risk for subsequent relapse and could be used as an indicator for secondary treatment intervention. 120 Combining the data from various laboratories, it is estimated that before treatment, the positivity of DTCs in the bone marrow is approximately 30%. 122, 123 Chemotherapy or bisphosphonates can reduce the positivity of DTCs. 123 Six months after treatment, DTCs remaining in the bone marrow after therapy define patients with an unfavourable prognosis. 122 Several studies have connected the presence of occult metastases in the bone marrow with a higher risk of recurrence. 124, 125 DTC status can be used to identify high-risk patients after chemotherapy and guide treatment decisions. However, DTC status after surgery was not associated with overall survival (Table 2) . 126 Analysis of bone marrow DTCs offers the possibility of developing targeted therapies to eliminate the residue of dormant cells. 127 The eradication of DTCs by bisphosphonates has already been demonstrated, and it was recently demonstrated that clodronate is effective in DTC elimination even after years of first diagnosis. 13 Treatment with clodronate has made a significant improvement in OS and significantly reduced the incidence of bone metastasis. 128 Preventing dormant DTCs in the bone marrow from reactivating cell cycling or kicking dormant cancer cells back into circulation may be strategies for preventing the relapse of metastatic disease.
β-adrenergic receptor antagonists, which interfere with proliferative re-activation norepinephrine (NE) signalling, may reduce cancer relapse or slow disease progression. 129 One potential strategy is finding a way to inhibit E-selectin, which could limit the ability of the cancer cells to travel into the bone and resurge as metastatic cancer. A combination of the E-selectin inhibitor GMI-1271, daunorubicin and cytarabine, was shown to result in a greater depletion of AML from the bone marrow. 130 Moreover, GMI-1271 was reported to enhance the response to chemotherapy. Bone marrow transplantation could also be a good choice after the surgery or chemotherapy.
| CONCLUSION
Dissemination of cancer cells is considered to be an early and ran- 
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